About Biothera
Biothera is a Healthcare company based in Eagan (United States) founded in 1997, and was acquired by Kerry Group in October 2015. Gluco-polysaccharides are developed to engage innate immune systems against cancer. Biothera has raised $18.14 million across 3 funding rounds from investors including Kerry Group. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include BeiGene, C4 Therapeutics and Erasca; 3 of its 3 listed competitors have raised funding.
Company details
Biothera was founded in 1997 in Eagan, United States, within the biotechnology sector. Gluco-polysaccharides are developed by the company to direct innate immune responses toward cancer cells. The firm was previously named Biopolymer Engineering, with the name changed to Biothera in March 2005. Imprime PGG, the lead drug candidate, is under evaluation in clinical trials for metastatic colorectal cancer, non-small cell lung cancer, and chronic lymphocytic leukemia.
- Headquarters Eagan, United States
- Stage Acquired
- SectorsHealthcare
- Website biothera.com
- Social LinkedIn
- Acquired by Kerry Group (Oct 2015)
- Total Equity Funding$18.14M (USD)
in 3 rounds
- Latest Funding Round$14.64M (USD), Private Equity Round
Mar 2018
- Investors
- Acquired byKerry Group
(Oct 2015)
Funding Insights of Biothera
Biothera has successfully raised a total of $18.14M across 3 strategic funding rounds. The most recent funding activity was a Private Equity Round of $14.64 million completed in March 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $18.14M
- Total Rounds 3
- Last Round Private Equity Round — $14.64M
- First Round $3.5M
(Apr 2010)
All 3 funding rounds of Biothera with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2018 | $14.64M | Private Equity Round | – | – | – |
| Oct 2014 | Debt – Conventional | – | – | – | |
| Apr 2010 | $3.5M | Private Equity Round | – | – | – |
1 investors in total: 1 institutional.
Investors in Biothera
Biothera has secured backing from 1 investor. Prominent investors backing the company include Kerry Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| kerrygroup.com |
Investor details for Biothera
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Biothera
4 dated milestones of Biothera across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Biothera is founded.
- Funding First funding round of $3.5M.
- Exit Acquired by Kerry Group.
- Funding Latest funding round, Private Equity Round, of $14.6M.
Competitors of Biothera
Biothera has 3 listed competitors in our database, 3 of them funded. They include BeiGene, C4 Therapeutics and Erasca.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. |
Detailed competitors of Biothera
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Biothera
Websites that share an audience with Biothera (biothera.com).
Websites whose visitors overlap most with Biothera. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
rspharmchem.com | rspharmchem.com | 100% | – | ||
aerokat.com | aerokat.com | 61% | – | ||
egyptianjournal.net78.net | egyptianjournal.net78.net | 60% | – | ||
| wellmune.com | 60% | 2.2K | #8,057,697 | View details | |
| fortitechpremixes.com | 60% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for Biothera
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Biothera (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biothera
Complete news archive for Biothera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biothera
Biothera was founded in 1997 and raised its 1st funding round 13 years after it was founded.
Biothera is headquartered in Eagan, United States. It is registered at Eagan, Minnesota, United States.
Biothera is a funded company, having raised a total of $18.14M across 3 funding rounds to date. The company's 1st funding round was a Private Equity Round of $3.5M, raised on Apr 2010.
Biothera was founded in 1997 in Eagan, United States, within the biotechnology sector. Gluco-polysaccharides are developed by the company to direct innate immune responses toward cancer cells. The firm was previously named Biopolymer Engineering, with the name changed to Biothera in March 2005. Imprime PGG, the lead drug candidate, is under evaluation in clinical trials for metastatic colorectal cancer, non-small cell lung cancer, and chronic lymphocytic leukemia.
Biothera's top competitors include C4 Therapeutics, BeiGene and Erasca.
Biothera has 1 investor. Key investors include Kerry Group.
Yes. Biothera was acquired by Kerry Group in October 2015.

